Briacell Therapeutics Corp (BCTX) - Total Liabilities
Based on the latest financial reports, Briacell Therapeutics Corp (BCTX) has total liabilities worth $3.66 Million USD as of April 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Briacell Therapeutics Corp growing its equity to track the company's year-over-year net asset growth rate.
Briacell Therapeutics Corp - Total Liabilities Trend (2006–2025)
This chart illustrates how Briacell Therapeutics Corp's total liabilities have evolved over time, based on quarterly financial data. See Briacell Therapeutics Corp free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Briacell Therapeutics Corp Competitors by Total Liabilities
The table below lists competitors of Briacell Therapeutics Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Stadlauer Malzfabrik Aktiengesellschaft
VI:STM
|
Austria | €257.19K |
|
Dusk Group Ltd
AU:DSK
|
Australia | AU$54.92 Million |
|
Broadpeak SA
PA:ALBPK
|
France | €30.55 Million |
|
3S KOREA Co. Ltd
KQ:060310
|
Korea | ₩14.25 Billion |
|
Ledlink Optics
TWO:5230
|
Taiwan | NT$1.02 Billion |
|
UTI Inc
KQ:179900
|
Korea | ₩114.22 Billion |
|
Grand Ocean Retail Group Ltd
TW:5907
|
Taiwan | NT$16.99 Billion |
|
SANGBO Corp
KQ:027580
|
Korea | ₩53.02 Billion |
Liability Composition Analysis (2006–2025)
This chart breaks down Briacell Therapeutics Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Briacell Therapeutics Corp market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Briacell Therapeutics Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Briacell Therapeutics Corp (2006–2025)
The table below shows the annual total liabilities of Briacell Therapeutics Corp from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-07-31 | $5.93 Million | -50.05% |
| 2024-07-31 | $11.88 Million | -71.25% |
| 2023-07-31 | $41.32 Million | -0.09% |
| 2022-07-31 | $41.36 Million | +8.96% |
| 2021-07-31 | $37.96 Million | +821.36% |
| 2020-07-31 | $4.12 Million | +263.51% |
| 2019-07-31 | $1.13 Million | -15.42% |
| 2018-07-31 | $1.34 Million | +51.25% |
| 2017-07-31 | $885.90K | +1723.19% |
| 2016-07-31 | $48.59K | -58.53% |
| 2015-07-31 | $117.17K | +368.01% |
| 2014-07-31 | $25.04K | -66.38% |
| 2013-07-31 | $74.46K | -73.78% |
| 2012-07-31 | $283.94K | -60.38% |
| 2011-07-31 | $716.66K | +2358.36% |
| 2010-07-31 | $29.15K | -54.58% |
| 2009-07-31 | $64.19K | +310.34% |
| 2008-07-31 | $15.64K | +63.21% |
| 2007-07-31 | $9.58K | -42.04% |
| 2006-07-31 | $16.54K | -- |
About Briacell Therapeutics Corp
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that… Read more